Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Dr. Alberto J. Montero is a Staff Physician in the Department of Solid Tumor Oncology. Dr. Montero’s clinical work focuses on breast cancer. Prior to joining the Cleveland Clinic, Dr. Montero was breast cancer site disease co-leader at the University of Miami Sylvester Comprehensive Cancer Center. Dr. Montero earned his medical degree from the University of Texas Medical Branch at Galveston, after which he completed a residency in internal medicine on the physician-scientist track at the University of Texas Houston Health Science Center. He then completed his fellowship training in hematology/oncology at the University of Texas M.D. Anderson Cancer Center. Dr. Montero's research interests include improvement of clinical outcomes in patients with breast cancer through the development of novel targeted therapies. He has been the principal investigator in over 30 clinical trials, and has co-authored over 50 peer reviewed publications. He has a particular interest in immune based therapies in breast cancer and other solid malignancies, and better understanding the various mechanisms by which tumors evade the immune system. Dr. Montero also has a keen interest in process improvement in oncology to develop more effective and efficient treatment strategies in breast cancer that lead to better clinical outcomes and ultimately superior quality of care for patients. He is a Six Sigma Green Belt. Dr. Montero has also published several studies examining the cost-effectiveness of several targeted therapies currently utilized for the treatment of metastatic breast cancer.
Breast Cancer, Cancer, Immunotherapy
MBA University of Miami Dec-2013
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 11/9/2015, Dr. Montero has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.